OJSC Pharmstandard (PHST) - Acquisition
RNS Number : 7052R
21 November 2012
Pharmstandard OJSC announces the Acquisition of a 100% stake in "LEKKO" CJSC.
Moscow, November 21, 2012 -O JSC Pharmstandard announces the acquisition of
100% stake in "LEKKO" CJSC.
On September 6, 2012 Russia's Federal Antimonopoly Service (FAS) has granted
approval for OJSC Pharmstandard's bid to acquire 100% of the voting shares of
"LEKKO" CJSC is a Russian innovative company which performs in the field of
research and development of highly effective drugs as well as their production
and distribution. The company has an 18-year track record of successful market
presence and it's products are a result of years of successful investments
into promising scientific researches in the field of traditional medicine.
"LEKKO" CJSC production facilities are located in Volginsky village (Vladimir
region). Annual output amounts to 50 million packs of 11 pharmaceutical
products. The company employs 400 highly-qualified professionals in the field
of medicine and pharmacy, biology and chemistry, management, marketing and
"LEKKO" CJSC 2011 audited revenues amounted to RUR684.4m. 3Q2012 revenues
Pharmstandard OJSC uses LEKKO facilities to produce Rinostop® and Acipol®.
3Q2012 sales of these drugs amounted to RUR111.6m and RUR266.04m accordingly.
Pharmstandard OJSC management believes that the acquisition of LEKKO is highly
effective for further successful production of Rinostop® and Acipol® as well
as for the expansion of business in general.
+7 495 970 00 30 ext.2824
About the Pharmstandard group of companies
The main sphere of activity of the enterprises comprising the Pharmstandard
group of companies, are developing and manufacturing of high-quality modern
pharmaceutical products which meet the requirements of the healthcare system
and the expectations of patients.
The most well-known Pharmstandard products today are Arbidol®, Complivit®,
Pentalgin®, Flucostat®, Phosphoglive®, Amixin®, Afobazol®, Rastan® and
Biosulin®. The Pharmstandard group of companies manufactures more than 250
pharmaceutical products, including medicines for the treatment of
cardio-vascular diseases, diabetes, growth hormone deficiency,
gastroenterological, neurological, contagious diseases, metabolic disorders,
cancer and other diseases. More than 100 Pharmstandard products (taking into
account all forms and dosages) are included in the list of Vital and Essential
In the period from 2004 to 2011 more than 60 new pharmaceutical products were
developed by Pharmstandard, in co-operation with the leading Russian
scientific centres. Pharmstandard is a participant in a joint bio-engineering
project, Generium, whose objective is the development of socially significant
pharmaceutical products within the framework of the state program of import
By 2011 the Сompany's aggregate production capacity has reached more than 1,46
billion packages per year. The production capacity of the Pharmstandard group
of companies comprises four modern pharmaceutical plants: JSC
Pharmstandard-Leksredstva (Kursk), JSC Pharmstandard-UfaVita (Ufa), JSC
Pharmstandard-Tomskhimpharm (Tomsk), JSC Pharmstandard-Biolek (Kharkov,
Ukraine) and the medical equipment and tools plant JSC TZMOI (Tyumen);
Pharmstandard LLC is responsible for the purchase and supply of raw materials
for manufacturing of pharmaceutical products at the production facilities of
the Pharmstandard group of companies.
All the production facilities of the Pharmstandard group of companies fully
comply with Russian national standards, while six production lines at JSC
Pharmstandard-Leksredstva have already received certificates of compliance
with the EU GMP standards. All the plants are expected to convert to European
GMP standards by 2014, according to the schedule approved by the company's
On 4 May 2007 Pharmstandard placed its shares during IPO on Russian Trading
System (RTS), Moscow Interbank Currency Exchange (MICEX) and Global Depositary
Receipts (GDR) at London Stock Exchange (LSE).
This information is provided by RNS
The company news service from the London Stock Exchange
ACQEADFFAFPAFFF -0- Nov/21/2012 14:00 GMT
Press spacebar to pause and continue. Press esc to stop.